Literature DB >> 10037497

Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms.

N Sergeant1, A Wattez, A Delacourte.   

Abstract

Pathological tau proteins that constitute the basic matrix of neuronal inclusions observed in numerous neurodegenerative disorders are disease specific. This is mainly the consequence of the aggregation of specific sets of tau isoforms according to the diseases, i.e., six isoforms in Alzheimer's disease (AD) and exclusively the three tau isoforms lacking the corresponding sequence of exon 10 (E10-) in Pick's disease (PiD). By using antibodies specific to the different tau isoforms and one- and two-dimensional gel electrophoresis followed by western blots, we demonstrate herein a third group of neurodegenerative disorders characterized by intraneuronal inclusions exclusively constituted of tau isoforms containing the sequence corresponding to exon 10, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Together, tau isoforms with exon 10 clearly differentiate three groups of neurodegenerative diseases: AD, PiD, and PSP/CBD. For each group, the neuropathological and clinical phenotypes are most likely related to specific sets of tau isoforms expressed by the vulnerable neuronal populations. The recently described mutations of the tau gene responsible for familial frontotemporal dementias also support this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037497     DOI: 10.1046/j.1471-4159.1999.0721243.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  57 in total

1.  Amyloid peptide toxicity and microtubule-stabilizing drugs.

Authors:  Mary L Michaelis; Yingxue Chen; Sarah Hill; Emily Reiff; Gunda Georg; Antonie Rice; Kenneth Audus
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

2.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

3.  Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics.

Authors:  L Varani; M G Spillantini; M Goedert; G Varani
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

Review 4.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

5.  Differential incorporation of tau isoforms in Alzheimer's disease.

Authors:  Marisol Espinoza; Rohan de Silva; Dennis W Dickson; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-05       Impact factor: 4.472

6.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 7.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 8.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

9.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

10.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.